Intra-Cellular shares mauled as a firestorm of speculation over adcomm cancellation spreads across BioTwitter
Rumors of bad news can flicker around the BioTwitter world in a heartbeat. And the impact can be devastating.
On Tuesday the target was Intra-Cellular Therapies $ITCI, and the rumor was pegged to an update on the FDA’s webpage that noted the agency was canceling the Psychopharmacologic Drugs Advisory Committee meeting for July 31 and the review planned for the biotech’s schizophrenia drug, lumateperone tosylate capsules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
